Baseline and 90-day data for patients with screen-detected atrial fibrillation who completed follow-up
| Characteristic | All patients with confirmed atrial fibrillation | Patients with actionable atrial fibrillation | ||||
|---|---|---|---|---|---|---|
| Baseline n = 51 | 90 days n = 51 | p value* | Baseline n = 13 | 90 days n = 13 | p value* | |
| Medications, no. (%) | ||||||
| Antiplatelet agent | 11 (22) | 12 (24) | > 0.99 | 4 (31) | 5 (39) | > 0.99 |
| Beta-blocker | 27 (53) | 30 (59) | 0.45 | 4 (31) | 7 (54) | 0.25 |
| Non-dihydropyridine calcium antagonist | 8 (16) | 6 (12) | 0.62 | 0 (0) | 0 (0) | NA |
| Digoxin | 10 (20) | 9 (18) | > 0.99 | 2 (15) | 2 (15) | NA |
| Class I antiarrhythmic drug | 0 (0) | 1 (2) | > 0.99 | 0 (0) | 0 (0) | NA |
| Class III antiarrhythmic drug | 0 (0) | 1 (2) | > 0.99 | 0 (0) | 0 (0) | NA |
| Any anticoagulant agent | 38 (75) | 48 (94) | 0.004 | 0 (0) | 10 (77) | 0.004 |
| Warfarin | 16 (31) | 18 (35) | 0.48 | 0 (0) | 2 (15) | 0.48 |
| Non–vitamin K antagonist anticoagulant agent | 22 (43) | 30 (59) | 0.013 | 0 (0) | 8 (62) | 0.013 |
| Heart rate, beats/min, mean ± SD | 76.6 ± 11.4 | 73.2 ± 12.0 | 0.083 | 81.4 ± 12.5 | 75.3 ± 13.1 | 0.21 |
| Systolic blood pressure, mm Hg, mean ± SD | 133.9 ± 17.6 | 129.9 ± 15.4 | 0.12 | 135.3 ± 17.2 | 127.2 ± 16.6 | 0.10 |
| Diastolic blood pressure, mm Hg, mean ± SD | 79.0 ± 11.7 | 76.2 ± 11.1 | 0.092 | 79.5 ± 13.1 | 77.9 ± 12.8 | 0.63 |
| Ttime in therapeutic range for those on warfarin, %, mean ± SD | 68.8 ± 23.5 | 68.1 ± 30.0 | 0.87 | NA | 75.0 ± 11.8 | NA |
| Patients with “adequate anticoagulation,”† no. (%) | 32 (63) | 42 (82) | 0.024 | 0 (0.0) | 10 (77) | NA |
Note: NA = not applicable, SD = standard deviation.
↵* Statistical comparisons were made using paired t tests for continuous variables and McNemar’s test for categorical variables. With the latter test, when the sum of discordant pairs was 0, this comparison could not be made (NA).
↵† “Adequate anticoagulation” was defined as either taking a non–vitamin K oral anticoagulant agent, or taking warfarin with a time in therapeutic range > 65%.